Search

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

84.47 0.23

Overview

Share price change

24h

Current

Min

84.06

Max

84.37

Key metrics

By Trading Economics

Income

7M

-121M

Sales

14M

25M

EPS

-1.14

Profit margin

-481.149

Employees

594

EBITDA

-4.7M

-131M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+1.68% upside

Dividends

By Acuity

Next Earnings

5 Nov 2026

Market Stats

By TradingEconomics

Market Cap

63M

8.9B

Previous open

84.24

Previous close

84.47

News Sentiment

By Acuity

68%

32%

293 / 340 Healthcare

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

11 Aug 2026, 23:56 UTC

News

GrowGeneration reports second-quarter net sales of $43.2 million, a 5.5% increase. Shares are higher in after-market trading following the earnings announcement.

11 Aug 2026, 23:56 UTC

News

Digital Realty Trust announced a quarterly dividend of $1.22 per share. Shares are trading higher in after-market hours following the announcement.

11 Aug 2026, 23:56 UTC

News

UBS maintains Buy rating on Rapid7 and raises price target to $12. Shares are trading higher in after-market hours, reflecting positive investor sentiment.

11 Aug 2026, 23:51 UTC

News

Codexis reported second-quarter revenues of $14.9 million, exceeding estimates. Shares are trading higher in after-market hours following the positive earnings report and guidance.

11 Aug 2026, 23:51 UTC

News

Matthews International Corp names Michael J. Whitehead as CEO, succeeding Joseph C. Bartolacci. Shares are trading higher in after-market hours amid leadership transition optimism.

11 Aug 2026, 23:46 UTC

News

Kilroy Realty Corp shares are higher in after-market trading following the departure of CFO Jeffrey Kuehling and the appointment of Eliott Trencher as interim CFO.

11 Aug 2026, 23:46 UTC

News

Whirlpool Corp reported Q2 earnings that missed revenue and adjusted EPS expectations. Shares were roughly flat in after-market trading following the results.

11 Aug 2026, 23:41 UTC

News

Clean Energy Fuels reported Q2 revenue of $106.4 million, exceeding expectations. The positive outlook for profitability growth boosted shares during after-market hours.

11 Aug 2026, 23:41 UTC

News
Correlated Moves

BlackRock is joining Nvidia's $500 billion AI infrastructure initiative, though concerns about funding sustainability have contributed to lower after-market trading for the firm.

11 Aug 2026, 23:41 UTC

News

Anterix shares fell in after-market trading despite a fiscal Q1 earnings beat, reporting net income of $240,000 and EPS of $0.01.

11 Aug 2026, 23:41 UTC

News
Social Media

H&R Block reported fiscal 2026 revenue of $3.95 billion, exceeding expectations, and raised its dividend by 10%, contributing to a significant after-market increase.

11 Aug 2026, 23:36 UTC

News

UBS upgraded Jabil Inc to Buy, maintaining a $430 price target. Shares are trading higher in after-market hours, supported by strong technical indicators.

11 Aug 2026, 23:31 UTC

News

Ameresco Inc shares rose in after-market trading following strong Q2 earnings, reporting $515.5 million in revenue and raising full-year adjusted EPS guidance to $1.25.

11 Aug 2026, 23:26 UTC

News
Social Media

Oracle Corp partners with Quantinuum to enhance cloud services with quantum computing. Shares are trading higher in after-market hours following the announcement.

11 Aug 2026, 23:11 UTC

News
Social Media

General Motors shares declined in after-market hours following the announcement of a $4.5 billion Supplier Inventory Financing Program and plans to sell its battery joint venture stake.

11 Aug 2026, 23:11 UTC

News
Social Media

Lumentum Holdings reported fiscal Q4 adjusted EPS of $3.23, exceeding estimates, and provided optimistic Q1 FY27 guidance, driving shares higher in after-market hours.

11 Aug 2026, 23:06 UTC

News

Uber Technologies Inc. sold its entire stake in Serve Robotics, raising investor concerns about its delivery strategy. Shares traded lower during after-market hours.

11 Aug 2026, 23:06 UTC

News

ATI Inc reported stronger second-quarter results, raising 2026 adjusted EBITDA guidance to $1.135 billion to $1.185 billion. Shares advanced in after-market hours.

11 Aug 2026, 23:06 UTC

News

KKR & Co Inc has invested in Crowe Advisory LLC, enhancing service capabilities. Shares are trading higher in after-market hours following the announcement.

11 Aug 2026, 23:06 UTC

News

SiTime Corp shares rose in after-market trading following a strong earnings report, highlighting 127% revenue growth and GAAP profitability.

11 Aug 2026, 23:06 UTC

News

Blue Owl Capital prices $750 million in Senior Notes due 2036, aiming to repay borrowings. Shares are higher in after-market trading following the announcement.

11 Aug 2026, 23:06 UTC

News

UBS initiated coverage on Century Aluminum Co with a Buy rating and a $60 price target, contributing to after-market gains.

11 Aug 2026, 23:02 UTC

News

Agree Realty Corp declared a monthly cash dividend of $0.267, a 4.3% increase, contributing to a modest rise in shares during after-market hours.

11 Aug 2026, 23:01 UTC

News

Siebert Financial Corp reports Q2 revenue of $31.2 million, up from $14.9 million last year. Shares are trading higher in after-market hours.

11 Aug 2026, 23:01 UTC

News

Century Communities has acquired the Harbor Pointe community in Santa Ana. Shares are lower during after-market hours despite this expansion in Southern California.

11 Aug 2026, 23:01 UTC

News

PagSeguro Digital shares rose in after-market hours following its Q2 earnings report, which showed a recurring net profit of 576 million reais, exceeding estimates.

11 Aug 2026, 23:01 UTC

News
Event

Astronics Corporation reported second-quarter net income of $35.1 million and raised full-year revenue guidance, boosting shares higher in after-market trading.

11 Aug 2026, 23:01 UTC

News

Arbor Realty Trust closed an $825 million collateralized loan obligation securitization, enhancing its balance sheet. Shares moved higher during after-market hours.

11 Aug 2026, 23:01 UTC

News

Stereotaxis reported second-quarter revenue of $7.67 million, missing estimates and down from last year's $8.90 million. Shares traded roughly flat in after-market hours.

11 Aug 2026, 23:01 UTC

News

Darling Ingredients announced a $150 million sale of production tax credits, boosting shares in after-market hours as investors react positively to the deal.

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

1.68% upside

12 Months Forecast

Average 85.56 USD  1.68%

High 95 USD

Low 80 USD

Based on 14 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

14 ratings

2

Buy

12

Hold

0

Sell

Sentiment

By Acuity

293 / 340 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat